US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust SMID Growth Strength ETF

30.90

+0.04770.15%

Post-market: 30.81-0.0927-0.30%16:10 EDT

Volume:271

Turnover:8K

Market Cap:29.36M

PE:- -

High:30.90

Open:30.81

Low:30.81

Close:30.86

52wk High:31.95

52wk Low:28.35

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.40

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FSGS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":30.9027,"timestamp":1780084800000,"preClose":30.855,"halted":0,"volume":271,"hourTrading":{"tag":"盘后","latestPrice":30.81,"preClose":30.9027,"latestTime":"16:10 EDT","volume":8,"amount":247.2216,"timestamp":1780085405130,"change":-0.0927,"changeRate":-0.003,"amplitude":0},"delay":0,"changeRate":0.0015459406903256835,"floatShares":950002,"shares":950002,"eps":0,"marketStatus":"Market Closed","change":0.0477,"latestTime":"05-29 16:00:00 EDT","open":30.81,"high":30.9027,"low":30.81,"amount":8381,"amplitude":0.003004,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":30.855,"sharesOutstanding":950002,"nav":30.94,"aum":29393061.88,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.81,"preClose":30.9027,"latestTime":"16:10 EDT","volume":8,"amount":247.2216,"timestamp":1780085405130,"change":-0.0927,"changeRate":-0.003,"amplitude":0},"volumeRatio":0.39935160624815796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":950002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.39935160624815796,"shares":950002,"dividePrice":0,"high":30.9027,"amplitude":0.003004,"preClose":30.855,"low":30.81,"week52Low":28.35,"pbRate":"--","week52High":31.95,"institutionHeld":0,"latestPrice":30.9027,"eps":0,"divideRate":0,"volume":271,"delay":0,"ttmEps":0,"open":30.81,"prevYearClose":30.4325,"prevWeekClose":30.8519,"prevMonthClose":30.6567,"prevQuarterClose":29.2082,"fiveDayClose":30.665,"twentyDayClose":30.6567,"sixtyDayClose":30.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635242733","title":"Press Release: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242733?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027. Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026. Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029. 30% reduction in uACR. In patients with severe focal segmental","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4555","BK4604","MAZE","TM","BK4007","BK4588","03160","BK4585","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633493381","title":"Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633493381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633493381?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  granted priority review to. Biologics License Application  for the accelerated approval of. atacicept in adult patients with IgA Nephropathy  with a. Prescription Drug User Fee Act  date of July 7, 2026. -- On track for U.S. commercial launch of atacicept in mid-2026, pending. -- Strong balance sheet expected to be sufficient to fund operations beyond. \"The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"During the first quarter, we made meaningful progress across key pre--commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to potentially be the first approved drug targeting both BAFF and APRIL in IgAN patients.\". IgAN in adults, and assigned a PDUFA target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4N35.SGD","LU1244550494.USD","LU1430594728.SGD","LU1732800096.USD","LU1035773651.USD","LU2324357040.USD","LU0868494708.USD","IE00BFSS7M15.SGD","LU2347655156.SGD","LU0795875169.SGD","LU1244550577.SGD","BK4588","LU0868494617.USD","LU0942090050.USD","BK4139","LU1718418525.SGD","BK4539","LU1585245621.USD","BK4534","BK4504","BK4566","IE00BFSS8Q28.SGD","BK4581","BK4209","TACI","BK4610","IE00BJJMRY28.SGD","LU0795875086.SGD","LU1732799900.SGD","LU0417517546.SGD","LU2279689827.SGD","IE00BJJMRX11.SGD","LU1074936037.SGD","BK4550","LU2347655073.USD","VERA","LU0256863811.USD","MCD","LU0912757837.SGD","FSGS","LU1069347547.HKD","IE00BJTD4V19.USD","LU1244550221.USD","LU0726765562.USD","IE00B7KXQ091.USD","BK4585","LU2133065610.SGD","IE0004445015.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453801","title":"Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453801","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453801?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Q1 2026 Vafseo (vadadustat) net product revenues grew to$15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289828/37519/en/Akebia-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Commercial-and-Pipeline-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","RBC","AKBA","BK4157","FSGS","IE00B64QTZ34.USD","LU2065731478.USD","MACE","MI","BK4077","IE00BLDYK493.USD","BK4183","BK4139","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144963","title":"Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144963","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144963?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924860,"startTime":"0","endTime":"0","summary":"FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million. FDA approval in FSGS expands total addressable FILSPARI patient population in the U.S. to more than 100,000; first FSGS patients treated within one week of approval. First new patient dosed in restarted Phase 3 HARMONY Study of pegtibatinase; Topline data expected 2H 2027. Travere Therapeutics, Inc.  today reported its first quarter 2026 financial results and provided a corporate update.Research and development (R&D) expenses for the first quarter of 2026 were $57.1 million, compared to $46.9 million for the same period in 2025. The increase is primarily attributable to the restart of the Phase 3 HARMONY Study of pegtibatinase in classical HCU. On a non-GAAP adjusted basis, R&D expenses were $51.5 million for the first quarter of 2026, compared to $42.2 million for the same period in 2025.As of March 31, 2026, the Company had cash, cash equiva","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","BK4539","TVTX","FSGS","BK4022","BK4007","R","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/FSGS\",params:#limit:6,delay:false,,,undefined,":[]}}